The document discusses the cost impact of hyperbaric oxygen therapy (HBOT) for diabetic foot ulcers (DFUs) in Europe, emphasizing its economic benefits and recommendations for care. It highlights the need for multidisciplinary care and equitable access to HBOT, noting significant barriers that prevent patients from receiving treatment. Overall, while HBOT is shown to reduce major amputations and potentially save costs for healthcare systems, very few DFU patients currently receive this therapy.